Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company
developing innovative targeted medicines and artificial
intelligence to find, fight and follow cancer, and ROTOP Pharmaka
GmbH, a leading radiopharmaceuticals company focused on diagnostics
and therapeutics, today announced an exclusive agreement under
which ROTOP agreed to develop and commercialize 1404 in Europe.
1404 is Progenics’ prostate specific membrane antigen
(PSMA)-targeted small molecule SPECT/CT imaging agent labeled with
technetium-99m that is designed to visualize prostate cancer.
“This European partnership with ROTOP further
expands the global reach of our PSMA-targeted prostate cancer
portfolio and establishes a development path forward for 1404 in
this important market, where SPECT/CT is the standard nuclear
imaging modality,” said Mark Baker, Chief Executive Officer of
Progenics. “ROTOP has deep experience developing, producing and
distributing radiopharmaceutical products, which makes them well
suited to advance the development of 1404 in Europe, and ultimately
improve physician treatment decisions of prostate cancer.”
Under the terms of the agreement, ROTOP will
receive an exclusive license to and will be responsible for the
development, regulatory approvals and commercialization of 1404 in
the covered European territory. In exchange, Progenics is eligible
for double-digit, tiered royalties based on future sales of 1404 in
Europe.
In the coming months, ROTOP will hold an expert
panel meeting with KOLs in the PSMA imaging field as well as
regulatory experts to review existing data on 1404 and obtain
guidance on the clinical development. Upon agreement on a path
forward, ROTOP will request a meeting with European regulators and
start a clinical trial in early 2020.
With the number of installed PET cameras in
Europe being less than a third of the installed SPECT cameras and
prostate cancer being the most frequent cancer in men, a capacity
shortage is already being seen for PSMA PET imaging in Europe and
this is expected to worsen once PSMA PET tracers are approved in
Europe. 1404 will address this problem as the first-in-class PSMA
tracer using SPECT scanners. A 1404-SPECT scan could be the key to
change the management of a large number of patients who have
limited access to PET.
“1404 is a complimentary fit to ROTOP’s growing
product line of radiopharmaceuticals, particularly technetium-99m
based imaging agents, for the diagnosis of a range of diseases,
including cancers,” said Jens Junker, Chief Executive Officer of
ROTOP. “Our collaboration with Progenics underscores our commitment
to developing new nuclear medicine and molecular imaging products
in parallel to our commercial operations, which distributes
radiopharmaceutical products to more than 30 countries.”
About 1404, an Imaging Agent Targeting
Prostate Specific Membrane Antigen
Progenics' molecular imaging radiopharmaceutical
product candidate 1404 targets the extracellular domain of prostate
specific membrane antigen (PSMA), a protein amplified on the
surface of > 95% of prostate cancer cells and a validated target
for the detection of primary and metastatic prostate cancer. 1404
is labeled with Technetium-99m, a gamma-emitting isotope that is
widely available, is easy to prepare, and is attractive for nuclear
medicine imaging applications. The image created provides the
opportunity to visualize cancer, potentially allowing for improved
detection and staging, more precise biopsies, and a targeted
treatment plan including active surveillance as a disease
management tool.
About PROGENICS
Progenics is an oncology company focused on the
development and commercialization of innovative targeted medicines
and artificial intelligence to find, fight and follow cancer,
including: therapeutic agents designed to treat cancer (AZEDRA®,
1095, and PSMA TTC); prostate-specific membrane antigen (“PSMA”)
targeted imaging agent for prostate cancer (PyL™); and imaging
analysis technology (aBSI and PSMA AI). Progenics has two
commercial products, AZEDRA, for the treatment of patients with
unresectable, locally advanced or metastatic pheochromocytoma or
paraganglioma (rare neuroendocrine tumors of neural crest origin)
who require systemic anticancer therapy; and RELISTOR®
(methylnaltrexone bromide) for the treatment of opioid-induced
constipation, which is partnered with Bausch Health Companies
Inc.
About ROTOP Pharmaka GmbH
ROTOP Pharmaka is a leading pharmaceutical
company that develops, produces and distributes cGMP compliant
radiopharmaceuticals for diagnostics and therapy in Nuclear
Medicine and Molecular Imaging and distributes them in more than 30
countries worldwide. With almost 20 years of experience in the
development, production, authorization and distribution of sterile
kits for radiolabeled pharmaceuticals ROTOP continuously expands
its product portfolio by developing new products and entering new
strategic partnerships.
This press release contains projections and
other "forward-looking statements" regarding future events.
Statements contained in this communication that refer to Progenics'
estimated or anticipated future results or other non-historical
facts are forward-looking statements that reflect Progenics'
current perspective of existing trends and information as of the
date of this communication. Forward looking statements generally
will be accompanied by words such as "anticipate," "believe,"
"plan," "could," "should," "estimate," "expect," "forecast,"
"outlook," "guidance," "intend," "may," "might," "will,"
"possible," "potential," "predict," "project," or other similar
words, phrases or expressions. Such statements are predictions
only, and are subject to risks and uncertainties that could cause
actual events or results to differ materially. These risks and
uncertainties include, among others, market acceptance for approved
products; the risk that the commercial launch of AZEDRA may not
meet revenue and income expectations; the cost, timing and
unpredictability of results of clinical trials and other
development activities and collaborations; the unpredictability of
the duration and results of regulatory review of New Drug
Applications (NDA) and Investigational NDAs; the inherent
uncertainty of outcomes in the intellectual property disputes such
as the dispute with the University of Heidelberg regarding
PSMA-617; our ability to successfully develop and commercialize
products that incorporate licensed intellectual property; the
effectiveness of the efforts of our partners to market and sell
products on which we collaborate and the royalty revenue generated
thereby; generic and other competition; the possible impairment of,
inability to obtain and costs of obtaining intellectual property
rights; possible product safety or efficacy concerns, general
business, financial, regulatory and accounting matters, litigation
and other risks. More information concerning Progenics and such
risks and uncertainties is available on its website, and in its
press releases and reports it files with the U.S. Securities and
Exchange Commission, including those risk factors included in its
Annual Report on Form 10-K for the year ended December 31, 2018, as
updated in its subsequent Quarterly Reports on Form 10-Q. Progenics
is providing the information in this press release as of its date
and, except as expressly required by law, Progenics disclaims any
intent or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events
or circumstances or otherwise.
Additional information concerning Progenics and
its business may be available in press releases or other public
announcements and public filings made after this release. For more
information, please visit www.progenics.com. Information on or
accessed through our website or social media sites is not included
in the company's SEC filings.
(PGNX-F)
Contact: |
Melissa DownsInvestor Relations(646)
975-2533mdowns@progenics.com |
Progenics Pharmaceuticals (NASDAQ:PGNX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Progenics Pharmaceuticals (NASDAQ:PGNX)
Historical Stock Chart
From Apr 2023 to Apr 2024